Search Page

1

Cite

Share

Wallerian degeneration: an emerging axon death pathway linking injury and disease.

Conforti L, Gilley J, Coleman MP. Conforti L, et al. Nat Rev Neurosci. 2014 Jun;15(6):394-409. doi: 10.1038/nrn3680. Nat Rev Neurosci. 2014. PMID: 24840802 Review.

Cite

Share

2

Cite

Share

dSarm/Sarm1 is required for activation of an injury-induced axon death pathway.

Osterloh JM, Yang J, Rooney TM, Fox AN, Adalbert R, Powell EH, Sheehan AE, Avery MA, Hackett R, Logan MA, MacDonald JM, Ziegenfuss JS, Milde S, Hou YJ, Nathan C, Ding A, Brown RH Jr, Conforti L, Coleman M, Tessier-Lavigne M, Züchner S, Freeman MR. Osterloh JM, et al. Among authors: conforti l. Science. 2012 Jul 27;337(6093):481-4. doi: 10.1126/science.1223899. Epub 2012 Jun 7. Science. 2012. PMID: 22678360 Free PMC article.

Cite

Share

3

Cite

Share

Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration.

Loreto A, Hill CS, Hewitt VL, Orsomando G, Angeletti C, Gilley J, Lucci C, Sanchez-Martinez A, Whitworth AJ, Conforti L, Dajas-Bailador F, Coleman MP. Loreto A, et al. Among authors: conforti l. Neurobiol Dis. 2020 Feb;134:104678. doi: 10.1016/j.nbd.2019.104678. Epub 2019 Nov 15. Neurobiol Dis. 2020. PMID: 31740269 Free article.

Cite

Share

4

Cite

Share

CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.

Agresta L, Lehn M, Lampe K, Cantrell R, Hennies C, Szabo S, Wise-Draper T, Conforti L, Hoebe K, Janssen EM. Agresta L, et al. Among authors: conforti l. J Immunother Cancer. 2020 Mar;8(1):e000245. doi: 10.1136/jitc-2019-000245. J Immunother Cancer. 2020. PMID: 32217758 Free PMC article.

Cite

Share

5

Cite

Share

Falls from height: orthopaedic and psychiatric evaluation.

Faggiani M, Aragno E, Aprato A, Rosso G, Conforti LG, Maina G, Massè A. Faggiani M, et al. Among authors: conforti lg. Acta Biomed. 2020 May 30;91(4-S):79-84. doi: 10.23750/abm.v91i4-S.9366. Acta Biomed. 2020. PMID: 32555080 Free PMC article.

Cite

Share

6

Cite

Share

Axonopathy in Huntington's disease.

Li JY, Conforti L. Li JY, et al. Among authors: conforti l. Exp Neurol. 2013 Aug;246:62-71. doi: 10.1016/j.expneurol.2012.08.010. Epub 2012 Aug 19. Exp Neurol. 2013. PMID: 22921535 Review.

Cite

Share

7

Cite

Share

Activation and degranulation of CAR-T cells using engineered antigen-presenting cell surfaces.

Dirar Q, Russell T, Liu L, Ahn S, Dotti G, Aravamudhan S, Conforti L, Yun Y. Dirar Q, et al. Among authors: conforti l. PLoS One. 2020 Sep 25;15(9):e0238819. doi: 10.1371/journal.pone.0238819. eCollection 2020. PLoS One. 2020. PMID: 32976541 Free PMC article.

Cite

Share

8

Cite

Share

Targeted knockdown of Kv1.3 channels in T lymphocytes corrects the disease manifestations associated with systemic lupus erythematosus.

Khodoun M, Chimote AA, Ilyas FZ, Duncan HJ, Moncrieffe H, Kant KS, Conforti L. Khodoun M, et al. Among authors: conforti l. Sci Adv. 2020 Nov 18;6(47):eabd1471. doi: 10.1126/sciadv.abd1471. Print 2020 Nov. Sci Adv. 2020. PMID: 33208373 Free PMC article.

Cite

Share

9

Cite

Share

Diversification of NAD biological role: the importance of location.

Di Stefano M, Conforti L. Di Stefano M, et al. Among authors: conforti l. FEBS J. 2013 Oct;280(19):4711-28. doi: 10.1111/febs.12433. Epub 2013 Aug 1. FEBS J. 2013. PMID: 23848828 Free article. Review.

Cite

Share

10

Cite

Share

A Compartmentalized Reduction in Membrane-Proximal Calmodulin Reduces the Immune Surveillance Capabilities of CD8⁺ T Cells in Head and Neck Cancer.

Chimote AA, Gawali VS, Newton HS, Wise-Draper TM, Conforti L. Chimote AA, et al. Among authors: conforti l. Front Pharmacol. 2020 Feb 28;11:143. doi: 10.3389/fphar.2020.00143. eCollection 2020. Front Pharmacol. 2020. PMID: 32184726 Free PMC article.

Cite

Share